Sallysamir Zahran | Drug Development | Best Researcher Award

Published on by Scientist Day

Global Scientist Day Awards

Sallysamir Zahran
Affiliation Egyptian Atomic Energy Authority
Country Egypt
Scopus ID 56490517500
Documents 5
Citations 116
h-index 3
Subject Area Drug Development
Event Global Scientist Day Awards

Sallysamir Zahran

Institution: Egyptian Atomic Energy Authority
Country: Egypt

Sallysamir Zahran is associated with the Egyptian Atomic Energy Authority and contributes to scientific research in the interdisciplinary field of drug development. Research activities have focused on developing innovative pharmaceutical and biomedical solutions supported by experimental investigations and collaborative scientific approaches. Scholarly publications indexed in Scopus demonstrate sustained academic engagement and measurable citation impact within the international research community.[1]

Abstract

Drug development requires integration of pharmaceutical science, biomedical research, analytical methodologies, and translational innovation. Sallysamir Zahran’s scholarly work contributes to these objectives through research that supports improved therapeutic strategies and scientific understanding. The publication record indexed by Scopus reflects consistent scientific productivity, while citation metrics indicate that the research has been referenced by fellow investigators within related disciplines.[1]

Keywords

Drug Development, Pharmaceutical Sciences, Biomedical Research, Therapeutic Innovation, Drug Discovery, Translational Medicine, Experimental Pharmacology, Clinical Research, Medical Science, Scientific Publications

Introduction

Modern drug development combines chemistry, biology, pharmacology, toxicology, and clinical science to produce safe and effective therapeutic interventions. Researchers working within this multidisciplinary environment contribute to improving healthcare outcomes through systematic experimentation, validation, and scientific communication. Publications indexed by international databases such as Scopus provide evidence of research visibility and scholarly dissemination.[1]

Research Profile

Sallysamir Zahran is affiliated with the Egyptian Atomic Energy Authority and has established an academic profile within the field of drug development. According to the available Scopus author profile, the researcher has produced five indexed scholarly documents, accumulated 116 citations, and attained an h-index of 3. These indicators demonstrate measurable scientific engagement and continued participation in internationally indexed research activities.[1]

Research Contributions

The research contributions emphasize experimental investigations supporting pharmaceutical innovation and biomedical applications. Published studies contribute to scientific knowledge related to therapeutic development, laboratory evaluation, and evidence-based research methodologies. Collaborative investigations further strengthen interdisciplinary knowledge exchange while encouraging reproducibility and scientific transparency.[2]

Publications

Research publications indexed within Scopus demonstrate scholarly dissemination in drug development and associated biomedical sciences. These publications collectively contribute to scientific literature through experimental evidence and peer-reviewed communication. Representative research articles include publications with Digital Object Identifiers (DOIs), enabling persistent scholarly access.[2]

Research Impact

Citation-based indicators provide evidence that the published research has received attention from the broader scientific community. The available Scopus metrics indicate 116 citations across five indexed documents with an h-index of 3, reflecting measurable academic influence and continued relevance within drug development research.[1]

Award Suitability

Based on the available scholarly indicators, Sallysamir Zahran demonstrates characteristics commonly associated with academic recognition, including peer-reviewed publications, international indexing, measurable citation performance, and contributions to drug development research. The research portfolio aligns with the objectives of the Global Scientist Day Awards, which recognize scientific excellence, innovation, and continued advancement of research across diverse disciplines.[3]

Conclusion

Sallysamir Zahran has established a recognized research profile within the field of drug development through scholarly publications, citation impact, and international indexing. The documented research activities contribute to scientific knowledge while supporting continued innovation in pharmaceutical and biomedical sciences. The available academic record reflects meaningful participation in global research and represents a profile suitable for consideration within international scientific recognition programs.[1]

References

  1. Elsevier. (2026). Scopus Author Details: Sallysamir Zahran, Author ID 56490517500. Scopus.
    https://www.scopus.com/authid/detail.uri?authorId=56490517500
  2. Novel pyrrole-sulfonamide derivatives as EGFR inhibitors and radiosensitizers in lung cancer.
    http://10.1016/j.bioorg.2025.109173
  3. Global Scientist Day Awards. (2026). Official Award Website.
    https://scientistday.org/

FURONG LI | Medical Discoveries | Outstanding Scientist Award

Published on by Scientist Day

Dr. FURONG LI | Medical Discoveries | Outstanding Scientist Award

Dr. FURONG LI, Shenzhen People’s Hospital, China

Dr. Fu-Rong Li, MD, PhD, is the Director of the Translational Medicine Collaborative Innovation Center at the First Affiliated Hospital (Shenzhen People’s Hospital) of the Southern University of Science and Technology, China. With a prolific academic background in clinical medicine, parasitology, and molecular biology, Dr. Li has made significant contributions in stem cell research, cancer immunotherapy, nanomedicine, and regenerative medicine. Over the course of his distinguished career, he has authored more than 80 peer-reviewed papers and holds several national patents. His pioneering work continues to influence the fields of translational and precision medicine both nationally and internationally.

🧬 Early Academic Pursuits

Dr. Fu-Rong Li embarked on his medical journey with an M.D. from Ningxia Medical College in 1984, followed by a Master’s degree in Parasitic Diseases with a focus on hydatidosis at Lanzhou Medical College in 1991. His academic dedication culminated in a Ph.D. in Molecular and Immune Parasitology from Tongji Medical University in 1999. These formative years laid the groundwork for his enduring contributions to translational medicine, immunotherapy, and stem cell biology. His research curiosity took root early, especially in the intersection of infectious diseases and immune response, which later evolved into a lifelong dedication to stem cell differentiation, regenerative medicine, and cancer immunotherapy.

🏥 Professional Endeavors

Dr. Li currently serves as the Director of the Translational Medicine Collaborative Innovation Center at Shenzhen People’s Hospital, affiliated with the Southern University of Science and Technology (SUSTech). Since 1999, he has held progressive roles from Assistant Professor to Professor, contributing significantly to the evolution of translational medicine in China. His early career included a stint as an Attending Physician in the Department of Digestive Medicine at Ningxia Medical University (1984–1988), followed by senior research and teaching roles at Lanzhou University’s Hydatid Research Laboratory. His professional trajectory showcases his dual capabilities in clinical practice and cutting-edge biomedical research.

🔬 Research Focus and Contributions

Dr. Li is internationally recognized for his pioneering work in stem cell biology, regenerative therapies, cancer diagnostics, and nanomedicine. His research contributions are vast, with over 85 peer-reviewed publications, covering topics like:

  • Differentiation of human induced pluripotent stem cells (iPSCs) into pancreatic β cells.

  • Cancer proteomics and exosomal signaling in lung adenocarcinoma.

  • Nano-immunodiagnostic tools for infectious and oncological diseases.

  • Single-cell analysis of non-coding RNAs in stem cell differentiation and immunity.

  • Development of novel multi-omics frameworks for understanding tumor biology.

His work has been published in prestigious journals such as Stem Cell Research & Therapy, Advanced Science, Cell Death & Disease, and NPJ Genomic Medicine.

🧪 Innovation and Patents

Dr. Li holds nine Chinese national invention patents, reflecting his commitment to translational applications of research. His inventions include:

  • Methods for iPSC to pancreatic cell differentiation via miRNAs.

  • Novel liquid chip-based miRNA detection kits.

  • Dual-labeled gold nanoprobes for diagnostic purposes.

  • Preparation methods for nano-magnetic drug microspheres.

These patents highlight his role as a scientific innovator and entrepreneurial researcher, bridging laboratory discoveries with real-world applications.

🏆 Accolades and Recognition

Dr. Li’s research excellence has earned him national and institutional recognition, especially for his work on diabetic wound healing, tumor immunotherapy, and stem cell engineering. His research has contributed to clinical advancements in personalized medicine and biomaterial-assisted stem cell therapy. He is frequently invited to speak at international conferences, reflecting his status as a leading expert in translational medicine and regenerative biology in China and beyond.

🌍 Impact and Influence

Through mentoring emerging scientists, supervising graduate students, and leading interdisciplinary collaborations, Dr. Li has cultivated a strong academic legacy. He is a bridge between fundamental biology and clinical medicine, influencing drug delivery systems, immunotherapy protocols, and biosensing platforms used globally. His work in lung cancer biology, in particular, has offered insights into cancer metastasis, immune checkpoint modulation, and exosome-mediated signaling pathways—laying the foundation for next-generation immunotherapies.

🔭 Legacy and Future Contributions

As a respected leader in Shenzhen’s biomedical ecosystem, Dr. Fu-Rong Li continues to shape the future of regenerative medicine, nanotechnology, and translational diagnostics. With over four decades of combined clinical and research expertise, he remains committed to advancing therapies for diabetes, cancer, and immune diseases. Looking ahead, Dr. Li is expected to contribute significantly to the integration of AI, single-cell sequencing, and precision medicine for real-time diagnostics and personalized treatment. His multidisciplinary approach ensures that his legacy will influence generations of scientists and physicians to come.

✍️Notable Publications

SLC4A7 suppresses lung adenocarcinoma oncogenesis by reducing lactate transport and protein lactylation

Author:  Haojie Yan , Qian He, Yubiao Gao, Xiaomei He, Haitao Luo, Lijuan Shao, Jun Dong, Furong Li

Journal: International Journal of Oncology .,

Year: 2025

Plant-Derived Extracellular Vesicles as Potential Emerging Tools for Cancer Therapeutics

Author: Lin Ding, Chih-Jung Chang, Min-Li Liang, Kang-Mei Dong, Fu-Rong Li

Journal: Advanced Therapeutics

Year: 2024

Novel DNA Biosensing Platform for Detecting HIV Integrase for Highly Sensitive and Quantitative HIV Detection, Diagnosis, and Therapeutic Monitoring

Author:  Fuming Chen, Jing Wang, Jie Ma, Li Song, Haojie Yan, Feng Wang, Zhengrong Yang, Furong Li